Previous 10 | Next 10 |
Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019. Mr. Tombesi brings over 30 years of extensive financial and accounting expertise to...
I had last recommended Epizyme ( EPZM ) as a promising pick in August 2018. Since then, the stock has picked up by 26.97%. The company's share price has moved in accordance with the news and sentiments for its lead asset Tazemetostat. I believe this trend will be continuing for a foreseeable...
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 108 weeks of public selections as part of this ongoing live forward-testing. In...
Epizyme (NASDAQ: EPZM ) +10.9% pre-market after reporting positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy....
Durable and Clinically Meaningful Responses Observed in Follicular Lymphoma Patients Regardless of EZH2 Mutational Status Tazemetostat NDA Submission for Follicular Lymphoma On Track for Fourth Quarter 2019 Company to Host Conference Call Today at 8:30 a.m. EDT Epizyme, Inc...
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more ...
Epizyme (NASDAQ: EPZM ) will host a conference call on June 21, at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. More news on: Epizyme, Inc., Read more ...
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, taze...
Epizyme ( EPZM ) specializes in an epigenetic therapy approach to human diseases, including cancers. This is a new field and potentially a revolutionary one. Proving a drug from the epigenetics platform can work well enough to get FDA approval would be a big advance for medicine and biotechnol...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...